Skip to main content
SpringerLink
Log in

Neoplasms of the Kidney and Bladder

  • Chapter
  • First Online:
Principles and Practice of Geriatric Surgery

  • 1632 Accesses

Abstract

The vast majority of human neoplasms appear to be coupled with the biology of aging. Over 70% of all cancers will occur in individuals over the age of 65 by the year 2030 [1, 2]. The age-specific incidence of many different types of cancer begin to rise steadily as we mature, and neoplasms arising from the kidney and bladder are of no exception. Approximately 88,200 men and 40,500 women developed a malignancy of the kidney or urinary bladder in 2009 [3]. The treatment of these malignancies in the elderly population requires careful consideration of factors such as life expectancy, incidence of treatment complications, and quality of life. This chapter reviews the incidence of kidney and bladder malignancies, the appropriate evaluation in the elderly, surgical and medical treatments available to treat the geriatric patient, and the complications associated with treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Edwards BK, Howe HL, Ries LA et al (2002) Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden. Cancer 94(10):2766–2792

    Article  PubMed  Google Scholar 

  2. Pantuck AJ, Zisman A, Belldegrun AS (2001) The changing natural history of renal cell carcinoma. J Urol 166(5):1611–1623

    Article  PubMed  CAS  Google Scholar 

  3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225–249

    Article  PubMed  Google Scholar 

  4. Dechet CB, Sebo T, Farrow G, Blute ML, Engen DE, Zincke H (1999) Prospective analysis of intraoperative frozen needle biopsy of solid renal masses in adults. J Urol 162(4):1282–1284; discussion 4–5

    Article  PubMed  CAS  Google Scholar 

  5. Nelson CP, Sanda MG (2002) Contemporary diagnosis and management of renal angiomyolipoma. J Urol 168(4 Pt 1):1315–1325

    PubMed  Google Scholar 

  6. Bissler JJ, Kingswood JC (2004) Renal angiomyolipomata. Kidney Int 66(3):924–934

    Article  PubMed  Google Scholar 

  7. Bosniak MA, Megibow AJ, Hulnick DH, Horii S, Raghavendra BN (1988) CT diagnosis of renal angiomyolipoma: the importance of detecting small amounts of fat. AJR Am J Roentgenol 151(3):497–501

    PubMed  CAS  Google Scholar 

  8. Choyke PL, Glenn GM, Walther MM, Zbar B, Linehan WM (2003) Hereditary renal cancers. Radiology 226(1):33–46

    Article  PubMed  Google Scholar 

  9. Hwang JJ, Uchio EM, Linehan WM, Walther MM (2003) Hereditary kidney cancer. Urol Clin North Am 30(4):831–842

    Article  PubMed  Google Scholar 

  10. Dhote R, Thiounn N, Debre B, Vidal-Trecan G (2004) Risk factors for adult renal cell carcinoma. Urol Clin North Am 31(2):237–247

    Article  PubMed  CAS  Google Scholar 

  11. Iliopoulos O, Eng C (2000) Genetic and clinical aspects of familial renal neoplasms. Semin Oncol 27(2):138–149

    PubMed  CAS  Google Scholar 

  12. Maher ER, Yates JR, Harries R et al (1990) Clinical features and natural history of von Hippel–Lindau disease. Q J Med 77(283):1151–1163

    Article  PubMed  CAS  Google Scholar 

  13. Latif F, Tory K, Gnarra J et al (1993) Identification of the von Hippel–Lindau disease tumor suppressor gene. Science 260(5112):1317–1320

    Article  PubMed  CAS  Google Scholar 

  14. Zambrano NR, Lubensky IA, Merino MJ, Linehan WM, Walther MM (1999) Histopathology and molecular genetics of renal tumors toward unification of a classification system. J Urol 162(4):1246–1258

    Article  PubMed  CAS  Google Scholar 

  15. Gnarra JR, Tory K, Weng Y et al (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7(1):85–90

    Article  PubMed  CAS  Google Scholar 

  16. Shuin T, Kondo K, Torigoe S et al (1994) Frequent somatic mutations and loss of heterozygosity of the von Hippel–Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 54(11):2852–2855

    PubMed  CAS  Google Scholar 

  17. Bosniak MA (1995) Observation of small incidentally detected renal masses. Semin Urol Oncol 13(4):267–272

    PubMed  CAS  Google Scholar 

  18. Bosniak MA, Birnbaum BA, Krinsky GA, Waisman J (1995) Small renal parenchymal neoplasms: further observations on growth. Radiology 197(3):589–597

    PubMed  CAS  Google Scholar 

  19. Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MA (2004) The natural history of incidentally detected small renal masses. Cancer 100(4):738–745

    Article  PubMed  Google Scholar 

  20. Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF (1971) Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 28(5):1165–1177

    Article  PubMed  CAS  Google Scholar 

  21. Thrasher JB, Paulson DF (1993) Prognostic factors in renal cancer. Urol Clin North Am 20(2):247–262

    PubMed  CAS  Google Scholar 

  22. Edge SB, American Joint Committee on Cancer, American Cancer Society (2010) AJCC cancer staging handbook: from the AJCC cancer staging manual, 7th edn. Springer, New York

    Google Scholar 

  23. Jayson M, Sanders H (1998) Increased incidence of serendipitously discovered renal cell carcinoma. Urology 51(2):203–205

    Article  PubMed  CAS  Google Scholar 

  24. Ritchie AW, Chisholm GD (1983) The natural history of renal carcinoma. Semin Oncol 10(4):390–400

    PubMed  CAS  Google Scholar 

  25. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr (1999) Rising incidence of renal cell cancer in the United States. JAMA 281(17):1628–1631

    Article  PubMed  CAS  Google Scholar 

  26. Homma Y, Kawabe K, Kitamura T et al (1995) Increased incidental detection and reduced mortality in renal cancer–recent retrospective analysis at eight institutions. Int J Urol 2(2):77–80

    Article  PubMed  CAS  Google Scholar 

  27. Carini M, Selli C, Barbanti G, Lapini A, Turini D, Costantini A (1988) Conservative surgical treatment of renal cell carcinoma: clinical experience and reappraisal of indications. J Urol 140(4):725–731

    PubMed  CAS  Google Scholar 

  28. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG (2006) The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 175(2):425–431

    Article  PubMed  Google Scholar 

  29. Abouassaly R, Lane BR, Novick AC (2008) Active surveillance of renal masses in elderly patients. J Urol 180(2):505–508; discussion 8–9

    Article  PubMed  Google Scholar 

  30. Klatte T, Patard JJ, de Martino M et al (2008) Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol 179(5):1719–1726

    Article  PubMed  Google Scholar 

  31. Campbell SC, Novick AC, Belldegrun A et al (2009) Guideline for management of the clinical T1 renal mass. J Urol 182(4):1271–1279

    Article  PubMed  Google Scholar 

  32. Washburn ZW, Dillman JR, Cohan RH, Caoili EM, Ellis JH (2009) Computed tomographic urography update: an evolving urinary tract imaging modality. Semin Ultrasound CT MR 30(4):233–245

    Article  PubMed  Google Scholar 

  33. Mulholland SG, Stefanelli JL (1990) Genitourinary cancer in the elderly. Am J Kidney Dis 16(4):324–328

    PubMed  CAS  Google Scholar 

  34. Bosniak MA (1997) The use of the Bosniak classification system for renal cysts and cystic tumors. J Urol 157(5):1852–1853

    Article  PubMed  CAS  Google Scholar 

  35. Davidson AJ, Hartman DS, Choyke PL, Wagner BJ (1997) Radiologic assessment of renal masses: implications for patient care. Radiology 202(2):297–305

    PubMed  CAS  Google Scholar 

  36. Trivedi H, Raman L, Benjamin H, Batwara R (2009) Lack of nephrotoxicity of gadodiamide in unselected hospitalized patients. Postgrad Med 121(5):166–170

    Article  PubMed  Google Scholar 

  37. Grobner T (2006) Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21(4):1104–1108

    Article  PubMed  CAS  Google Scholar 

  38. Altun E, Martin DR, Wertman R, Lugo-Somolinos A, Fuller ER III, Semelka RC (2009) Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy – report from two U.S. universities. Radiology 253(3):689–696

    Article  PubMed  Google Scholar 

  39. Thomsen HS (2009) How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States. Radiol Clin North Am 47(5):871–875; vii

    Article  PubMed  Google Scholar 

  40. Thomsen HS, Morcos SK, Barrett BJ (2008) Contrast-induced nephropathy: the wheel has turned 360 degrees. Acta Radiol 49(6):646–657

    Article  PubMed  CAS  Google Scholar 

  41. Idee JM, Port M, Dencausse A, Lancelot E, Corot C (2009) Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin North Am 47(5):855–869; vii

    Article  PubMed  Google Scholar 

  42. Robson CJ, Churchill BM, Anderson W (1969) The results of radical nephrectomy for renal cell carcinoma. J Urol 101(3):297–301

    PubMed  CAS  Google Scholar 

  43. Pantuck AJ, Zisman A, Dorey F et al (2003) Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer 97(12):2995–3002

    Article  PubMed  Google Scholar 

  44. Hellsten S, Johnsen J, Berge T, Linell F (1990) Clinically unrecognized renal cell carcinoma. Diagnostic and pathological aspects. Eur Urol 18(Suppl 2):23

    Google Scholar 

  45. Golimbu M, Joshi P, Sperber A, Tessler A, Al-Askari S, Morales P (1986) Renal cell carcinoma: survival and prognostic factors. Urology 27(4):291–301

    Article  PubMed  CAS  Google Scholar 

  46. Giuliani L, Giberti C, Martorana G, Rovida S (1990) Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol 143(3):468–473; discussion 73–74

    PubMed  CAS  Google Scholar 

  47. Kontak JA, Campbell SC (2003) Prognostic factors in renal cell carcinoma. Urol Clin North Am 30(3):467–480

    Article  PubMed  Google Scholar 

  48. Ramon J, Goldwasser B, Raviv G, Jonas P, Many M (1991) Long-term results of simple and radical nephrectomy for renal cell carcinoma. Cancer 67(10):2506–2511

    Article  PubMed  CAS  Google Scholar 

  49. Siemer S, Lehmann J, Loch A et al (2005) Current TNM classification of renal cell carcinoma evaluated: revising stage T3a. J Urol 173(1):33–37

    Article  PubMed  CAS  Google Scholar 

  50. Thrasher JB, Crawford ED (1993) Current management of invasive and metastatic transitional cell carcinoma of the bladder. J Urol 149(5):957–972

    PubMed  CAS  Google Scholar 

  51. Haas NB, Uzzo R (2008) Adjuvant therapy for renal cell carcinoma. Curr Oncol Rep 10(3):245–252

    Article  PubMed  CAS  Google Scholar 

  52. Clayman RV, Kavoussi LR, Soper NJ et al (1991) Laparoscopic nephrectomy: initial case report. J Urol 146(2):278–282

    PubMed  CAS  Google Scholar 

  53. Meraney AM, Gill IS (2002) Financial analysis of open versus laparoscopic radical nephrectomy and nephroureterectomy. J Urol 167(4):1757–1762

    Article  PubMed  Google Scholar 

  54. Ono Y, Hattori R, Gotoh M, Yoshino Y, Yoshikawa Y, Kamihira O (2005) Laparoscopic radical nephrectomy for renal cell carcinoma: the standard of care already? Curr Opin Urol 15(2):75–78

    Article  PubMed  Google Scholar 

  55. Portis AJ, Yan Y, Landman J et al (2002) Long-term followup after laparoscopic radical nephrectomy. J Urol 167(3):1257–1262

    Article  PubMed  Google Scholar 

  56. Chacko JK, Koyle MA, Mingin GC, Furness PD III (2007) Minimally invasive open renal surgery. J Urol 178(4 Pt 2):1575–1577; discussion 7–8

    Article  PubMed  Google Scholar 

  57. Eden CG, Haigh AC, Carter PG, Coptcoat MJ (1994) Laparoscopic nephrectomy results in better postoperative pulmonary function. J Endourol 8(6):419–422; discussion 22–23

    Article  PubMed  CAS  Google Scholar 

  58. Badger WJ, Gallagher BL, Szeluga DJ, Winfield HN (2008) Hurdles to helium gas laparoscopy and a readily available alternative. J Endourol 22(11):2455–2459

    Article  PubMed  Google Scholar 

  59. Lai FC, Kau EL, Ng CS, Fuchs GJ (2007) Laparoscopic nephrectomy outcomes of elderly patients in the 21st century. J Endourol 21(11):1309–1313

    Article  PubMed  Google Scholar 

  60. Najarian JS, Chavers BM, McHugh LE, Matas AJ (1992) 20 years or more of follow-up of living kidney donors. Lancet 340(8823):807–810

    Article  PubMed  CAS  Google Scholar 

  61. Goldfarb DA, Matin SF, Braun WE et al (2001) Renal outcome 25 years after donor nephrectomy. J Urol 166(6):2043–2047

    Article  PubMed  CAS  Google Scholar 

  62. Bijol V, Mendez GP, Hurwitz S, Rennke HG, Nose V (2006) Evaluation of the nonneoplastic pathology in tumor nephrectomy specimens: predicting the risk of progressive renal failure. Am J Surg Pathol 30(5):575–584

    Article  PubMed  Google Scholar 

  63. Huang WC, Levey AS, Serio AM et al (2006) Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 7(9):735–740

    Article  PubMed  Google Scholar 

  64. Castilla EA, Liou LS, Abrahams NA et al (2002) Prognostic importance of resection margin width after nephron-sparing surgery for renal cell carcinoma. Urology 60(6):993–997

    Article  PubMed  Google Scholar 

  65. Uzzo RG, Novick AC (2001) Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J Urol 166(1):6–18

    Article  PubMed  CAS  Google Scholar 

  66. Lee CT, Katz J, Shi W, Thaler HT, Reuter VE, Russo P (2000) Surgical management of renal tumors 4 cm. or less in a contemporary cohort. J Urol 163(3):730–736

    Article  PubMed  CAS  Google Scholar 

  67. Stephenson AJ, Hakimi AA, Snyder ME, Russo P (2004) Complications of radical and partial nephrectomy in a large contemporary cohort. J Urol 171(1):130–134

    Article  PubMed  Google Scholar 

  68. Thomas AA, Aron M, Hernandez AV, Lane BR, Gill IS (2009) Laparoscopic partial nephrectomy in octogenarians. Urology 74(5):1042–1046

    Article  PubMed  Google Scholar 

  69. Michaels MJ, Rhee HK, Mourtzinos AP, Summerhayes IC, Silverman ML, Libertino JA (2002) Incomplete renal tumor destruction using radio frequency interstitial ablation. J Urol 168(6):2406–2409; discussion 9–10

    Article  PubMed  Google Scholar 

  70. Rendon RA, Kachura JR, Sweet JM et al (2002) The uncer­tainty of radio frequency treatment of renal cell carcinoma: findings at immediate and delayed nephrectomy. J Urol 167(4):1587–1592

    Article  PubMed  Google Scholar 

  71. Matlaga BR, Zagoria RJ, Woodruff RD, Torti FM, Hall MC (2002) Phase II trial of radio frequency ablation of renal cancer: evaluation of the kill zone. J Urol 168(6):2401–2405

    Article  PubMed  Google Scholar 

  72. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124

    Article  PubMed  CAS  Google Scholar 

  73. Balducci L (2009) Supportive care in elderly cancer patients. Curr Opin Oncol 21(4):310–317

    Article  PubMed  Google Scholar 

  74. Balducci L (2009) Pharmacology of antineoplastic medications in older cancer patients. Oncology (Williston Park) 23(1):78–85

    Google Scholar 

  75. Yagoda A, Abi-Rached B, Petrylak D (1995) Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol 22(1):42–60

    PubMed  CAS  Google Scholar 

  76. Milowsky MI, Nanus DM (2003) Chemotherapeutic strategies for renal cell carcinoma. Urol Clin North Am 30(3):601–609, x

    Article  PubMed  Google Scholar 

  77. Kroog GS, Motzer RJ (2008) Systemic therapy for metastatic renal cell carcinoma. Urol Clin North Am 35(4):687–701, ix

    Article  PubMed  Google Scholar 

  78. Dutcher JP, Fisher RI, Weiss G et al (1997) Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 3(3):157–162

    PubMed  CAS  Google Scholar 

  79. Negrier S, Escudier B, Lasset C et al (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med 338(18):1272–1278

    Article  PubMed  CAS  Google Scholar 

  80. Yang JC, Sherry RM, Steinberg SM et al (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21(16):3127–3132

    Article  PubMed  CAS  Google Scholar 

  81. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271–2281

    Article  PubMed  CAS  Google Scholar 

  82. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134

    Article  PubMed  CAS  Google Scholar 

  83. Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456

    Article  PubMed  CAS  Google Scholar 

  84. Gore ME, Szczylik C, Porta C et al (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10(8):757–763

    Article  PubMed  CAS  Google Scholar 

  85. Schultzel M, Saltzstein SL, Downs TM, Shimasaki S, Sanders C, Sadler GR (2008) Late age (85 years or older) peak incidence of bladder cancer. J Urol 179(4):1302–1305; discussion 5–6

    Article  PubMed  Google Scholar 

  86. Prout GR Jr, Wesley MN, Yancik R, Ries LA, Havlik RJ, Edwards BK (2005) Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study. Cancer 104(8):1638–1647

    Article  PubMed  Google Scholar 

  87. Konety BR, Joslyn SA (2003) Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program. J Urol 170(5):1765–1771

    Article  PubMed  Google Scholar 

  88. Briggs NC, Young TB, Gilchrist KW, Vaillancourt AM, Messing EM (1992) Age as a predictor of an aggressive clinical course for superficial bladder cancer in men. Cancer 69(6):1445–1451

    Article  PubMed  CAS  Google Scholar 

  89. Mariani AJ, Mariani MC, Macchioni C, Stams UK, Hariharan A, Moriera A (1989) The significance of adult hematuria: 1,000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis. J Urol 141(2):350–355

    PubMed  CAS  Google Scholar 

  90. Britton JP, Dowell AC, Whelan P, Harris CM (1992) A community study of bladder cancer screening by the detection of occult urinary bleeding. J Urol 148(3):788–790

    PubMed  CAS  Google Scholar 

  91. Vikram R, Sandler CM, Ng CS (2009) Imaging and staging of transitional cell carcinoma: part 1, lower urinary tract. AJR Am J Roentgenol 192(6):1481–1487

    Article  PubMed  Google Scholar 

  92. Sidransky D, Von Eschenbach A, Tsai YC et al (1991) Identification of p53 gene mutations in bladder cancers and urine samples. Science 252(5006):706–709

    Article  PubMed  CAS  Google Scholar 

  93. Feng Z, Hu W, Teresky AK, Hernando E, Cordon-Cardo C, Levine AJ (2007) Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. Proc Natl Acad Sci U S A 104(42):16633–16638

    Article  PubMed  CAS  Google Scholar 

  94. Stuart GR, Oda Y, de Boer JG, Glickman BW (2000) Mutation frequency and specificity with age in liver, bladder and brain of lacI transgenic mice. Genetics 154(3):1291–1300

    PubMed  CAS  Google Scholar 

  95. Taylor JA 3rd, Kuchel GA (2009) Bladder cancer in the elderly: clinical outcomes, basic mechanisms, and future research direction. Nat Clin Pract Urol 6(3):135–144

    Article  PubMed  Google Scholar 

  96. Bornman DM, Mathew S, Alsruhe J, Herman JG, Gabrielson E (2001) Methylation of the E-cadherin gene in bladder neoplasia and in normal urothelial epithelium from elderly individuals. Am J Pathol 159(3):831–835

    Article  PubMed  CAS  Google Scholar 

  97. Habuchi T, Takahashi T, Kakinuma H et al (2001) Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer. Oncogene 20(4):531–537

    Article  PubMed  CAS  Google Scholar 

  98. Gu J, Spitz MR, Zhao H et al (2005) Roles of tumor suppressor and telomere maintenance genes in cancer and aging–an epidemiological study. Carcinogenesis 26(10):1741–1747

    Article  PubMed  CAS  Google Scholar 

  99. Koch M, Hill GB, McPhee MS (1986) Factors affecting recurrence rates in superficial bladder cancer. J Natl Cancer Inst 76(6):1025–1029

    PubMed  CAS  Google Scholar 

  100. Cooksley CD, Avritscher EB, Grossman HB et al (2008) Clinical model of cost of bladder cancer in the elderly. Urology 71(3):519–525

    Article  PubMed  Google Scholar 

  101. Ro JY, Staerkel GA, Ayala AG (1992) Cytologic and histologic features of superficial bladder cancer. Urol Clin North Am 19(3):435–453

    PubMed  CAS  Google Scholar 

  102. Fitzpatrick JM, West AB, Butler MR, Lane V, O’Flynn JD (1986) Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J Urol 135(5):920–922

    PubMed  CAS  Google Scholar 

  103. Torti FM, Lum BL, Aston D et al (1987) Superficial bladder cancer: the primacy of grade in the development of invasive disease. J Clin Oncol 5(1):125–130

    PubMed  CAS  Google Scholar 

  104. Heney NM, Ahmed S, Flanagan MJ et al (1983) Superficial bladder cancer: progression and recurrence. J Urol 130(6):1083–1086

    PubMed  CAS  Google Scholar 

  105. Kiemeney LA, Witjes JA, Heijbroek RP, Verbeek AL, Debruyne FM (1993) Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 150(1):60–64

    PubMed  CAS  Google Scholar 

  106. Allard P, Bernard P, Fradet Y, Tetu B (1998) The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br J Urol 81(5):692–698

    Article  PubMed  CAS  Google Scholar 

  107. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J (2000) Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 164(3 Pt 1):680–684

    Article  PubMed  CAS  Google Scholar 

  108. Holmang S, Hedelin H, Anderstrom C, Johansson SL (1995) The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 153(6):1823–1826; discussion 6–7

    Article  PubMed  CAS  Google Scholar 

  109. Pagano F, Garbeglio A, Milani C, Bassi P, Pegoraro V (1987) Prognosis of bladder cancer I. Risk factors in superficial transitional cell carcinoma. Eur Urol 13(3):145–149

    PubMed  CAS  Google Scholar 

  110. Althausen AF, Prout GR Jr, Daly JJ (1976) Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 116(5):575–580

    PubMed  CAS  Google Scholar 

  111. Wallace DM, Hindmarsh JR, Webb JN et al (1979) The role of multiple mucosal biopsies in the management of patients with bladder cancer. Br J Urol 51(6):535–540

    Article  PubMed  CAS  Google Scholar 

  112. Farrow GM, Utz DC, Rife CC, Greene LF (1977) Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder. Cancer Res 37(8 Pt 2):2794–2798

    PubMed  CAS  Google Scholar 

  113. Bostwick DG (1992) Natural history of early bladder cancer. J Cell Biochem Suppl 16I:31–38

    Article  PubMed  CAS  Google Scholar 

  114. Prout GR Jr, Griffin PP, Daly JJ (1987) The outcome of conservative treatment of carcinoma in situ of the bladder. J Urol 138(4):766–770

    PubMed  Google Scholar 

  115. Witjes JA, Mungan NA, Debruyne FM (2000) Management of superficial bladder cancer with intravesical chemotherapy: an update. Urology 56(1):19–21

    Article  PubMed  CAS  Google Scholar 

  116. Peyromaure M, Zerbib M (2004) T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival. BJU Int 93(1):60–63

    Article  PubMed  CAS  Google Scholar 

  117. Soloway MS, Sofer M, Vaidya A (2002) Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 167(4):1573–1583

    Article  PubMed  Google Scholar 

  118. Smith JA Jr, Labasky RF, Cockett AT, Fracchia JA, Montie JE, Rowland RG (1999) Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol 162(5):1697–1701

    Article  PubMed  Google Scholar 

  119. Sylvester RJ, der MA Van, Lamm DL (2002) Intravesical Bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168(5):1964–1970

    Article  PubMed  CAS  Google Scholar 

  120. Cookson MS, Sarosdy MF (1992) Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette–Guerin therapy. J Urol 148(3):797–801

    PubMed  CAS  Google Scholar 

  121. Bohle A, Bock PR (2004) Intravesical bacille Calmette–Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63(4):682–686; discussion 6–7

    Article  PubMed  CAS  Google Scholar 

  122. Herr HW (1997) High-risk superficial bladder cancer: transurethral resection alone in selected patients with T1 tumor. Semin Urol Oncol 15(3):142–146

    PubMed  CAS  Google Scholar 

  123. Miladi M, Peyromaure M, Zerbib M, Saighi D, Debre B (2003) The value of a second transurethral resection in evaluating patients with bladder tumours. Eur Urol 43(3):241–245

    Article  PubMed  Google Scholar 

  124. Herr HW (1997) Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol 80(5):762–765

    Article  PubMed  CAS  Google Scholar 

  125. Oosterlinck W, Lobel B, Jakse G, Malmstrom PU, Stockle M, Sternberg C (2002) Guidelines on bladder cancer. Eur Urol 41(2):105–112

    Article  PubMed  Google Scholar 

  126. Esrig D, Freeman JA, Stein JP, Skinner DG (1997) Early cystectomy for clinical stage T1 transitional cell carcinoma of the bladder. Semin Urol Oncol 15(3):154–160

    PubMed  CAS  Google Scholar 

  127. Barlow LJ, McKiernan JM, Benson MC (2009) The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. World J Urol 27(3):331–335

    Article  PubMed  CAS  Google Scholar 

  128. Martinez-Pineiro JA, Jimenez Leon J, Martinez-Pineiro L Jr et al (1990) Bacillus Calmette–Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol 143(3):502–506

    PubMed  CAS  Google Scholar 

  129. Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K (2005) Bacillus Calmette–Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a ­meta-analysis of the published results of randomized clinical trials. J Urol 174(1):86–91; discussion 2

    Article  PubMed  CAS  Google Scholar 

  130. Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M (2003) Intravesical Bacillus Calmette–Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev (3):CD003231

    Google Scholar 

  131. Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M (2000) Intravesical Bacillus Calmette–Guerin in Ta and T1 bladder cancer. Cochrane Database Syst Rev (4):CD001986

    Google Scholar 

  132. Lamm DL (1991) Comparison of BCG with other intravesical agents. Urology 37(5 Suppl):30–32

    Article  PubMed  CAS  Google Scholar 

  133. Lamm DL, Blumenstein BA, Crissman JD et al (2000) Maintenance bacillus Calmette–Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163(4):1124–1129

    Article  PubMed  CAS  Google Scholar 

  134. Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E et al (2005) Has a 3-fold decreased dose of bacillus Calmette–Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 174(4 Pt 1):1242–1247

    Article  PubMed  Google Scholar 

  135. Herr HW (2007) Age and outcome of superficial bladder cancer treated with bacille Calmette-Guerin therapy. Urology 70(1):65–68

    Article  PubMed  Google Scholar 

  136. Droller MJ (1992) Treatment of regionally advanced bladder cancer. An overview. Urol Clin North Am 19(4):685–693

    PubMed  CAS  Google Scholar 

  137. Silverman DT, Hartge P, Morrison AS, Devesa SS (1992) Epidemiology of bladder cancer. Hematol Oncol Clin North Am 6(1):1–30

    PubMed  CAS  Google Scholar 

  138. Tekes A, Kamel I, Imam K et al (2005) Dynamic MRI of bladder cancer: evaluation of staging accuracy. AJR Am J Roentgenol 184(1):121–127

    PubMed  Google Scholar 

  139. Kim B, Semelka RC, Ascher SM, Chalpin DB, Carroll PR, Hricak H (1994) Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Radiology 193(1):239–245

    PubMed  CAS  Google Scholar 

  140. Tanimoto A, Yuasa Y, Imai Y et al (1992) Bladder tumor staging: comparison of conventional and gadolinium-enhanced dynamic MR imaging and CT. Radiology 185(3):741–747

    PubMed  CAS  Google Scholar 

  141. Herr HW (2001) Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 19(1):89–93

    PubMed  CAS  Google Scholar 

  142. Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB (2003) Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst 95(8):588–597

    Article  PubMed  Google Scholar 

  143. Skinner DG, Lieskovsky G (1984) Contemporary cystectomy with pelvic node dissection compared to preoperative radiation therapy plus cystectomy in management of invasive bladder cancer. J Urol 131(6):1069–1072

    PubMed  CAS  Google Scholar 

  144. Reisinger SA, Mohiuddin M, Mulholland SG (1992) Combined pre- and postoperative adjuvant radiation therapy for bladder ­cancer–a ten year experience. Int J Radiat Oncol Biol Phys 24(3):463–468

    Article  PubMed  CAS  Google Scholar 

  145. Wammack R, Wricke C, Hohenfellner R (2002) Long-term results of ileocecal continent urinary diversion in patients treated with and without previous pelvic irradiation. J Urol 167(5):2058–2062

    Article  PubMed  Google Scholar 

  146. Chamie K, Hu B, Devere White RW, Ellison LM (2008) Cystectomy in the elderly: does the survival benefit in younger patients translate to the octogenarians? BJU Int 3:284–290

    Article  Google Scholar 

  147. Nielsen ME, Shariat SF, Karakiewicz PI et al (2007) Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol 51(3):699–706; discussion 8

    Article  PubMed  Google Scholar 

  148. Weizer AZ, Joshi D, Daignault S et al (2007) Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancer. J Urol 177(4):1287–1293

    Article  PubMed  Google Scholar 

  149. Stroumbakis N, Herr HW, Cookson MS, Fair WR (1997) Radical cystectomy in the octogenarian. J Urol 158(6):2113–2117

    Article  PubMed  CAS  Google Scholar 

  150. Roehrborn CG, Sagalowsky AI, Peters PC (1991) Long-term patient survival after cystectomy for regional metastatic transitional cell carcinoma of the bladder. J Urol 146(1):36–39

    PubMed  CAS  Google Scholar 

  151. Leissner J, Ghoneim MA, Abol-Enein H et al (2004) Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol 171(1):139–144

    Article  PubMed  CAS  Google Scholar 

  152. Smith AB, Nielsen ME, Wallen EM, Pruthi RS. Current status of robot-assisted radical cystectomy. Curr Opin Urol. 2009 Oct 28

    Google Scholar 

  153. Pruthi RS, Smith A, Wallen EM (2008) Evaluating the learning curve for robot-assisted laparoscopic radical cystectomy. J Endourol 22(11):2469–2474

    Article  PubMed  Google Scholar 

  154. Sternberg CN (1995) The treatment of advanced bladder cancer. Ann Oncol 6(2):113–126

    PubMed  CAS  Google Scholar 

  155. Loehrer PJ Sr, Einhorn LH, Elson PJ et al (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10(7):1066–1073

    PubMed  Google Scholar 

  156. Logothetis CJ, Dexeus FH, Finn L et al (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8(6):1050–1055

    PubMed  CAS  Google Scholar 

  157. Harker WG, Meyers FJ, Freiha FS et al (1985) Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol 3(11):1463–1470

    PubMed  CAS  Google Scholar 

  158. Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N (1997) Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15(12):3441–3445

    PubMed  CAS  Google Scholar 

  159. Bamias A, Efstathiou E, Moulopoulos LA et al (2005) The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Ann Oncol 16(2):307–313

    Article  PubMed  CAS  Google Scholar 

  160. Castagneto B, Zai S, Marenco D et al (2004) Single-agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment. Oncology 67(1):27–32

    Article  PubMed  CAS  Google Scholar 

  161. Linardou H, Aravantinos G, Efstathiou E et al (2004) Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Urology 64(3):479–484

    Article  PubMed  Google Scholar 

  162. Bamias A, Lainakis G, Kastritis E et al (2007) Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment. Oncology 73(5–6):290–297

    Article  PubMed  CAS  Google Scholar 

  163. Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349(9):859–866

    Article  PubMed  CAS  Google Scholar 

  164. Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E (1996) Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: nordic cystectomy trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol 155(6):1903–1906

    Article  PubMed  CAS  Google Scholar 

  165. Salminen E (1990) Recurrence and treatment of urinary bladder cancer after failure in radiotherapy. Cancer 66(11):2341–2345

    Article  PubMed  CAS  Google Scholar 

  166. Given RW, Parsons JT, McCarley D, Wajsman Z (1995) Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: a five-year follow-up. Urology 46(4):499–504; discussion 5

    Article  PubMed  CAS  Google Scholar 

  167. Brennan P, Bogillot O, Cordier S et al (2000) Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer 86(2):289–294

    Article  PubMed  CAS  Google Scholar 

  168. Morrison AS, Buring JE, Verhoek WG et al (1984) An international study of smoking and bladder cancer. J Urol 131(4):650–654

    PubMed  CAS  Google Scholar 

  169. Piper JM, Tonascia J, Matanoski GM (1985) Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med 313(5):292–295

    Article  PubMed  CAS  Google Scholar 

  170. Fortuny J, Kogevinas M, Zens MS et al (2007) Analgesic and anti-inflammatory drug use and risk of bladder cancer: a population based case control study. BMC Urol 7:13

    Article  PubMed  CAS  Google Scholar 

  171. Porpaczy P, Schramek P (1981) Analgesic nephropathy and phenacetin-induced transitional cell carcinoma - analysis of 300 patients with long-term consumption of phenacetin-containing drugs. Eur Urol 7(6):349–354

    PubMed  CAS  Google Scholar 

  172. Cole P, Hoover R, Friedell GH (1972) Occupation and cancer of the lower urinary tract. Cancer 29(5):1250–1260

    Article  PubMed  CAS  Google Scholar 

  173. Case RA, Pearson JT (1954) Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. II. Further consideration of the role of aniline and of the manufacture of auramine and magenta (fuchsine) as possible causative agents. Br J Ind Med 11(3):213–216

    PubMed  CAS  Google Scholar 

  174. Gaertner RR, Trpeski L, Johnson KC (2004) A case-control study of occupational risk factors for bladder cancer in Canada. Cancer Causes Control 15(10):1007–1019

    Article  PubMed  Google Scholar 

  175. Travis LB, Curtis RE, Glimelius B et al (1995) Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin’s lymphoma. J Natl Cancer Inst 87(7):524–530

    Article  PubMed  CAS  Google Scholar 

  176. O’Keane JC (1988) Carcinoma of the urinary bladder after treatment with cyclophosphamide. N Engl J Med 319(13):871

    PubMed  Google Scholar 

  177. Chrouser K, Leibovich B, Bergstralh E, Zincke H, Blute M (2005) Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J Urol 174(1):107–110; ­discussion 10–11

    Article  PubMed  Google Scholar 

  178. Sella A, Dexeus FH, Chong C, Ro JY, Logothetis CJ (1989) Radiation therapy-associated invasive bladder tumors. Urology 33(3):185–188

    Article  PubMed  CAS  Google Scholar 

  179. Delnay KM, Stonehill WH, Goldman H, Jukkola AF, Dmochowski RR (1999) Bladder histological changes associated with chronic indwelling urinary catheter. J Urol 161(4):1106–1108; discussion 8–9

    Article  PubMed  CAS  Google Scholar 

  180. Michaud DS (2007) Chronic inflammation and bladder cancer. Urol Oncol 25(3):260–268

    Article  PubMed  CAS  Google Scholar 

  181. Sala M, Cordier S, Chang-Claude J et al (2000) Coffee consumption and bladder cancer in nonsmokers: a pooled analysis of case-control studies in European countries. Cancer Causes Control 11(10):925–931

    Article  PubMed  CAS  Google Scholar 

  182. Zeegers MP, Dorant E, Goldbohm RA, van den Brandt PA (2001) Are coffee, tea, and total fluid consumption associated with bladder cancer risk? Results from the Netherlands Cohort Study. Cancer Causes Control 12(3):231–238

    Article  PubMed  CAS  Google Scholar 

  183. Takkouche B, Etminan M, Montes-Martinez A (2005) Personal use of hair dyes and risk of cancer: a meta-analysis. JAMA 293(20):2516–2525

    Article  PubMed  CAS  Google Scholar 

  184. Sontag JM (1980) Experimental identification of genitourinary carcinogens. Urol Clin North Am 7(3):803–814

    PubMed  CAS  Google Scholar 

  185. Villanueva CM, Fernandez F, Malats N, Grimalt JO, Kogevinas M (2003) Meta-analysis of studies on individual consumption of chlorinated drinking water and bladder cancer. J Epidemiol Community Health 57(3):166–173

    Article  PubMed  CAS  Google Scholar 

  186. Marshall G, Ferreccio C, Yuan Y et al (2007) Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. J Natl Cancer Inst 99(12):920–928

    Article  PubMed  CAS  Google Scholar 

  187. Kurth KH, Denis L, Bouffioux C et al (1995) Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 31A(11):1840–1846

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Yale University School of Medicine, 800 Howard Avenue, 3rd Floor, New Haven, CT, 06519, USA

    Edward M. Uchio

Authors
  1. Edward M. Uchio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juan S. Calderon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jonathan J. Hwang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edward M. Uchio .

Editor information

Editors and Affiliations

  1. School of Medicine, Department of Surgery, Yale University, New Haven, 06520, Connecticut, USA

    Ronnie Ann Rosenthal

  2. Downstate Medical Center, State University of New York, Clarkson Ave. 450, Brooklyn, 11203, New York, USA

    Michael E. Zenilman

  3. , Chairman, Department of Surgery, Sinai Hospital, 2401 West Belvedere Avenue, Baltimore, 21215, Maryland, USA

    Mark R. Katlic

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Uchio, E.M., Calderon, J.S., Hwang, J.J. (2011). Neoplasms of the Kidney and Bladder. In: Rosenthal, R., Zenilman, M., Katlic, M. (eds) Principles and Practice of Geriatric Surgery. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-6999-6_80

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-6999-6_80

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-6998-9

  • Online ISBN: 978-1-4419-6999-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation